Showing results (161-170 of 194) with videos related to
Sort By:
Pageof 20
Annals of the Rheumatic Diseases|June 7, 2019
Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severityNikolaos I Panousis, George K Bertsias, Halit Ongen, et al.Annals of the Rheumatic Diseases|July 23, 2025
Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosusPanagiotis Garantziotis, Lorenzo Beretta, Julius Lindblom, et al.Journal of Cellular Physiology|September 17, 2016
Differential Expression of miR-4520a Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF)Helen Latsoudis, Mir-Farzin Mashreghi, Joachim R Grün, et al.Rheumatology (Oxford, England)|January 11, 2022
Performance of the systemic lupus erythematosus risk probability index in a cohort of undifferentiated connective tissue diseaseAbdulsamet Erden, Hakan Apaydın, Antonis Fanouriakis, et al.Clinical and Experimental Rheumatology|March 11, 2017
Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription databasePetros P Sfikakis, Vasiliki-Kalliopi Bournia, Prodromos Sidiropoulos, et al.RMD Open|March 2, 2023
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to considerAgata Burska, Javier Rodríguez-Carrio, Robert Biesen, et al.Arthritis & Rheumatology (Hoboken, N.J.)|May 16, 2023
Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II TrialDavid R Jayne, Jürgen Steffgen, Juanita Romero-Diaz, et al.The Journal of Infectious Diseases|February 24, 2021
The Activin/Follistatin Axis Is Severely Deregulated in COVID-19 and Independently Associated With In-Hospital MortalityEvgenia Synolaki, Vasileios Papadopoulos, Georgios Divolis, et al.RMD Open|March 7, 2023
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to considerJavier Rodríguez-Carrio, Agata Burska, P G Conaghan, et al.Annals of the Rheumatic Diseases|March 1, 2023
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practiceJavier Rodríguez-Carrio, Agata Burska, Philip G Conaghan, et al.Pageof 20